Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2022-01-10 |
Resource Citation "58" Version "24" Updated "2023-12-06 00:56:00+0000"
url: https://fevir.net/resources/Citation/58
identifier: FEvIR Object Identifier/58
version: 1.0.0-ballot
title: Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
status: active
date: 2022-01-10 13:29:15+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use') | FHIR Resource (Citation Artifact Classifier#fhir-resource) |
jurisdiction: World (m49.htm#001)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
author: Brian S. Alper:
| Style | Text |
| Computable Publishing (Citation Summary Style#comppub) | 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) [FHIR Resource], version 4. Contributors: Brian S. Alper, Joanne Dehnbostel, Khalid Shahin [Authors]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 55. Created December 17, 2020. Revised December 21, 2020. Accessed March 13, 2021. Available at: https://fevir.net/resources/Evidence/55. Computable resource at: https://fevir.net/resources/Evidence/55. |
| Type | ResourceReference |
| derived-from | https://fevir.net/resources/Evidence/55 "Fourteen_day_mortality_remdesivir_vs_placebo_meta_analysis_ACTT_1_Wang_et_al_WHO_SOLIDARITY" |
citedArtifact
identifier: FEvIR Object Identifier/55
dateAccessed: 2021-03-13
Versions
Value 4 StatusDates
Activity Actual Period Created (Cited Artifact Status Type#created) true ?? --> 2020-12-17 Titles
Type Language Text Primary title (Title Type#primary) English (Tags for the Identification of Languages[4.0.1]#en) 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY). Abstracts
Type Language Text Copyright Primary human use (Cited Artifact Abstract Type#primary-human-use) English (Tags for the Identification of Languages#en) COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis https://creativecommons.org/licenses/by-nc-sa/4.0/ publicationForm
PublishedIns
Type Title Publisher PublisherLocation Database (Published In Type#D019991) Fast Evidence Interoperability Resources (FEvIR) Platform : Computable Publishing LLC Ipswich, MA, USA lastRevisionDate: 2020-12-21
language: English (Tags for the Identification of Languages[4.0.1]#en)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
WebLocations
Classifier Url JSON (Artifact Url Classifier#json), Computable resource (Artifact Url Classifier#computable-resource) 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: FHIR Resource (Citation Artifact Classifier#fhir-resource)
classification
type: FHIR Resource (Citation Artifact Classifier#fhir-resource)
classifier: Evidence (All FHIR Types#Evidence)
classification
type: keyword major topic (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")
classifier: remdesivir (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text"), COVID-19 (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text"), pharmaceutical treatment (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")
contributorship
complete: true
entry
identifier:
https://orcid.org//0000-0003-4300-4928name: Brian S. Alper
telecom: balper@computablepublishing.com
forenameInitials: BS
affiliation: : Computable Publishing LLC
contributionType: Conceptualization (Artifact Contribution Type#conceptualization), Data curation (Artifact Contribution Type#data-curation), Supervision (Artifact Contribution Type#supervision)
role: Author/Creator (Contributor Role#author)
correspondingContact: true
entry
name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com
forenameInitials: J
affiliation: : Computable Publishing LLC
contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Data curation (Artifact Contribution Type#data-curation)
role: Author/Creator (Contributor Role#author)
correspondingContact: false
entry
name: Khalid Shahin
telecom: kshahin@computablepublishing.com
forenameInitials: K
affiliation: : Computable Publishing LLC
contributionType: Software (Artifact Contribution Type#software)
role: Author/Creator (Contributor Role#author)
correspondingContact: false
Generated Narrative: Practitioner #contributor0
identifier:
https://orcid.org//0000-0003-4300-4928name: Brian S. Alper
telecom: balper@computablepublishing.com
Generated Narrative: Practitioner #contributor1
name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com
Generated Narrative: Practitioner #contributor2
name: Khalid Shahin
telecom: kshahin@computablepublishing.com
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-04-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change